Key Takeaways:
hVIVO PLC shares jumped more than 7 percent after the company announced a £6 million contract to conduct an influenza human challenge trial for an unnamed biopharmaceutical company.
"The cadence of wins reinforces our view that the company's integrated model, combining participant recruitment, clinical operations and in-house virology analytics, represents a differentiated and increasingly attractive offering," analysts at Cavendish said in a note.
The contract will see hVIVO evaluate a monoclonal antibody using its specialized Influenza Human Challenge Study Model. Revenue from the deal will be recognized across 2026 and 2027. The announcement pushed shares to 7.99p, adding to a year-to-date gain of approximately 25 percent. Cavendish, which acts as hVIVO's corporate broker, reiterated its 'buy' rating and a 16.5p price target on the stock.
The deal provides a "step change" to revenue visibility for 2026, a crucial development for hVIVO as it recovers from a difficult 2025 where revenue fell 25 percent. The new business adds to a rebuilding order book that includes a major pertussis trial for ILiAD Biotechnologies.
The study will take place at hVIVO's quarantine facilities in Canary Wharf, London. It will involve deliberately exposing healthy volunteers to a pathogen under controlled conditions to evaluate the new drug's effectiveness, a method the company specializes in.
hVIVO's business model faced headwinds in 2025 as market conditions in the contract research sector deteriorated, causing adjusted EBITDA to fall to £2.2 million from £17.3 million the prior year. However, analysts forecast revenues to recover to £50.3 million this year, representing 7.5 percent growth.
The company's strong position in the niche field of human challenge trials, combined with a debt-free balance sheet and £14.3 million in net cash, provides a solid foundation for its recovery.
The succession of contract wins signals that management's strategy to leverage its integrated platform is gaining traction with clients. Investors will now look to the company's capital markets day on June 11 for further details on its growth outlook and path back to profitability, which Cavendish does not expect to see at the operating level until 2027.
This article is for informational purposes only and does not constitute investment advice.
